Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [3]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-60882 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- RNASE2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: QFTWAQWFET QHINMTSQQC TNAMQV
- Concentration
- 0.1 mg/mL
Submitted references An Increasing Trend of Eosinophilic Esophagitis in Korea and the Clinical Implication of the Biomarkers to Determine Disease Activity and Treatment Response in Eosinophilic Esophagitis.
Kim GH, Park YS, Jung KW, Kim M, Na HK, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Dellon ES, Jung HY
Journal of neurogastroenterology and motility 2019 Oct 30;25(4):525-533
Journal of neurogastroenterology and motility 2019 Oct 30;25(4):525-533
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of RNASE2 in human bone marrow shows strong cytoplasmic positivity in a subset of cells. Samples were probed using a RNASE2 Polyclonal Antibody (Product # PA5-60882).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of RNASE2 in human bone marrow and cerebral cortex tissues using RNASE2 Polyclonal Antibody (Product # PA5-60882). Corresponding RNASE2 RNA-seq data are presented for the same tissues.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of RNASE2 in human cerebral cortex using RNASE2 Polyclonal Antibody (Product # PA5-60882) shows low expression as expected.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Histologic findings before and after treatment in a patient with eosinophilic esophagitis (EoE). (A) Hematoxylin and eosin staining shows an elevated eosinophil counts (x400) and normalization after therapy (x400). (B) The tryptase staining shows elevated number of stained cells and normalization after therapy (x400). (C) The eosinophil-derived neurotoxin staining shows an elevated number of stained cells (x400) and normalization after therapy (x400). (D) Eotaxin-3 staining shows elevated number of stained cells (x400) and normalization after therapy (x400).
